The Physidia – Spindial partnership has been awarded the frequent home hemodialysis tender issued by the Tuscany region in Italy
Physidia, European leader in frequent home dialysis, and Spindial, leader in the dialysis market in Italy, have been awarded one of the most important public tenders held in Europe for the supply of all the devices needed to deliver frequent home hemodialysis.
After less than a year of partnership between the French company Physidia, proprietary owner of the home dialysis technology named S³, and the Italian company Spindial, developer of sterile lactate solutions for frequent home dialysis, have been awarded one of the largest European public tenders for the supply and delivery of frequent home hemodialysis treatments which represent the new therapeutic option for patients suffering from chronic renal failure.
The tender issued by the Tuscany Region in Italy, in the year 2021, had as objectives to identify, analyze, evaluate and contract the best technologies on the market as to home dialysis treatments to be made available to its patients. Among these technologies, an important therapeutic strategy was represented by frequent home hemodialysis that guarantees patients a significant improvement in their quality of life.
Spindial, participating in this tender process with S³ technology and with its sterile dialysis solutions as well as its dialyzers was recognized as the best frequent home therapy, both in qualitative as well as economic terms.
From a qualitative point of view, the Spindial – Physidia offer obtained the best score in particular with regard to: the “user friendly” interface, the ergonomics and the digital medicine capacity assured by the equipment in addition to the broad range of dialyzers and dialysis solutions in bags that Nephrologists can prescribe in order to accurately personalize dialysis therapy for each patient.
The Framework Agreement, awarded to Spindial, for a maximum value of € 7.550.400 over 48 months, will allow to provide, with the Physidia S³ equipment, up to 75.000 treatments supporting at least 70 patients continuously for the entire duration of the Framework Agreement.
“This award by the Tuscany Region to our partner Spindial is a breakthrough event for the home dialysis population in Italy. The innovative S³-Physidia technology will provide hemodialysis treatments at the patient’s home safely and effectively”, commented Didier Candelot, CEO of Physidia.
Marcello Grondelli, CEO of Spindial, added: “We are sure that other Regions in Italy will follow the example of the Tuscany Region which has shown a great strategic vision and determination in order to adopt and spread health care therapies, which, for chronic patients, favors home care.”
Created in Angers (France) in 2011, Physidia developed and commercializes S³, the first system designed specifically for patients who need daily hemodialysis whilst ensuring their safety and comfort. This innovation is based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a treatment performed in total autonomy. The short treatment, which lasts in average 2 hours on a daily basis, can be performed at home in full autonomy without compromising the quality of the renal dialysis nor its safety. The system fully favors the patients’ social and professional reintegration, an approach which is impossible to consider for patients who must go to dialysis centers.
The company registered three patents for its hemodialysis system S³. The device and a part of the consumables are produced in France. Physidia is operating directly in France and through distributor partners in the rest of Europe. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient.